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Abstract
Background—Overactive bladder (OAB) is a common condition affecting the elderly. The
mainstay of treatment for OAB is medical therapy with anticholinergics. However, adverse events
have been reported with this class of drugs including cognitive changes.
Objective—To investigate the effect of an anticholinergic medication on cognitive function in
postmenopausal women being treated for OAB.
Study Design—Prospective cohort study conducted from January to December 2010, with 12-
week follow-up after medication initiation.
Setting—Urogynecology clinic at one academic medical center.
Patients—Women age 55 or older seeking treatment for OAB and opting for anticholinergic
therapy were recruited.
Intervention—Baseline cognitive function was assessed via the Hopkins Verbal Learning Test –
Revised Form (HVLT-R) (and its 5 subscales), the Orientation, Memory & Concentration (OMC)
short form, and the Mini-Cog evaluation. After initiation of trospium chloride extended release,
cognitive function was reassessed at Day 1, Week 1, Week 4 and Week 12. Bladder function was
assessed via three condition-specific quality of life questionnaires. Secondary outcomes included
change in bladder symptoms, correlation between cognitive and bladder symptoms, and overall
medication compliance.
Main Outcome Measure—Change in HVLT-R score at Week 4 after medication initiation,
compared to baseline (pre-medication) score.
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Results—Of 50 women enrolled, 35 completed the assessment. Average age was 70.4 years and
77.1% had previously taken anticholinergic medication for OAB. At enrollment 65.7% had severe
overactive bladder and 71.4% had severe urge incontinence. Cognitive function showed an initial
decline on Day 1 in HVLT-R total score (p=0.037), HVLT-R Delayed Recognition subscale
(p=0.011) and HVLT-R Recognition Bias subscale (p=0.01). At Week 1 the HVLT-R Learning
subscale declined from baseline (p=0.029). All HVLT-R scores normalized by Week 4. OMC
remained stable throughout. The Mini-Cog nadired at a 90.9% pass rate at Week 4. OAB
symptoms did not improve until Week 4, based on questionnaire scores (p<0.05).
Conclusion—Cognitive function exhibited early changes after initiation of trospium chloride but
normalized within four weeks. Cognitive changes occurred weeks prior to OAB symptom
improvement. Surveillance for cognitive changes with anticholinergic use should be part of OAB
management.
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INTRODUCTION
Overactive bladder (OAB) is a common condition affecting the elderly population.[1] OAB
is defined by the International Continence Society (ICS) as “urinary urgency, usually
accompanied by frequency and nocturia, with or without urge urinary incontinence”.[2] OAB
afflicts more than 38 million Americans, and 1 in every 3 elderly adults.[1,2] OAB has far-
reaching consequences for both physical and mental health: skin breakdown due to leakage,
sleep disturbance, fall-related injuries, depression, prolonged hospital stays, admission to a
nursing home and lower quality of life.[1, 3–5] OAB is an embarrassing condition that
interferes with not only social functioning but also a wide range of activities of daily
living.[4] Annual direct costs of OAB in the US -- including diagnostic tests, physician
visits, medications, treatment procedures, supplies such as pads, diapers and home care --
totaled over $12 billion in 2005.[6] This is comparable to breast cancer ($12.7 billion) and
osteoporosis ($13.8 billion). There are also indirect costs: loss of work productivity, time off
from work for treatment, and inability to maintain employment due to OAB. [7,8] We can
decrease the significant healthcare and economic burdens associated with OAB by investing
more healthcare resources in effective and safe treatments.
The mainstay of treatment for OAB is pharmacotherapy -- the primary class of drugs is
anticholinergics. Because anticholinergic receptors are found throughout the body, the side
effects of these drugs are common and widespread.[9–11] One of the most serious adverse
effects is cognitive impairment. The central nervous system (CNS) contains all five
anticholinergic receptors, which influence a wide array of cognitive function: learning,
memory, language, arousal/attention, and visuospatial/sensory/motor processing.[9,10,12] It is
therefore not surprising that anticholinergic medications have been linked to cognitive
impairment.[13,14] Multiple cognitive effects have been reported with anticholinergic use:
memory changes, blurred vision, somnolence, hallucinations, confusion, and delirium. All of
these cognitive impairments are more prevalent in the elderly, possibly due to the increased
CNS absorption of anticholinergics in this population.[9, 15–18] Given that 1 in 3 elderly
adults suffers from OAB, the proportion of elderly using anticholinergics for OAB alone is
high. Because anticholinergics are also used to treat many other medical conditions, there is
potential for compounding of drug-induced cognitive impairment. One study of almost 6000
elderly patients found that 59% were taking at least one anticholinergic; and 10% were
taking up to three.[3] Therefore, it is becoming increasingly critical to understand the
magnitude of adverse anticholinergic effects on cognitive function. Currently, there is no
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standard of practice for OAB management. Management of anticholinergic use in the elderly
must involve monitoring of: functional status, comorbidities, concurrent medication use, and
active surveillance for adverse events – including the development of cognitive impairment.
Our primary aim was to investigate the effect of a specific anticholinergic, trospium chloride
extended release, on cognitive function in postmenopausal women in a clinic setting.
Secondary aims included understanding the severity of OAB in this clinic population, the
timing of changes in cognitive function and OAB symptom improvement, and medication
compliance.
METHODS
After approval by the Institutional Review Board at the University of North Carolina at
Chapel Hill (UNC), we conducted a prospective cohort study assessing cognitive function in
women initiating an anticholinergic medication for the treatment for OAB. STROBE
(STrengthening the Reporting of OBservational studies in Epidemiology) guidelines were
followed.[19] Women age 55 or older seeking treatment for OAB were recruited from the
Female Pelvic Medicine and Reconstructive Surgery clinic between January and December
2010. Initially the age of recruitment was 65 and older but we amended this within the first
three months of the study after finding it difficult to meet recruitment goals. After being
counseled by their physician on treatment options for OAB, women opting for
anticholinergic medication were offered enrollment in the study, which would entail
treatment with trospium chloride extended release. After complete description of the study
to the subjects, written informed consent was obtained. Subjects received a small monetary
compensation for completing the follow-up assessments but medication costs were not
covered.
Baseline cognitive function was assessed prior to anticholinergic start via the Hopkins
Verbal Learning Test – Revised Form (HVLT-R), the Orientation, Memory & Concentration
(OMC) short form, and the Mini-Cog evaluation.[20–22] This battery of tests comprise
validated measures of cognitive function commonly used in the geriatric population. The
Mini-Cog test is a very brief three-minute cognitive screening test that is useful in detecting
mild cognitive impairment, dementia and early stage Alzheimer's, and is not dependent on
education level or language. It includes a drawing test and verbal recall. Both the accuracy
of the clock face and the verbal recall are scored. The HVLT-R is a verbal memory test that
involves reading subjects a list of 12 words and having them recall the words both
immediately and after a delay of 25 minutes. There are 6 versions which provide differing
sets of 12 words. The HVLT-R generates a total score and seven subscale scores, including
Total Recall, Delayed Recall, Delayed Recognition, Learning, Retention, Discrimination
Index and Recognition Bias. The HVLT-R has a low risk of ceiling effects (even for the
non-dementia population) and is not affected by gender or education. It is easy to
administer, quick and a well tolerated tool for the screening of dementia. The OMC is a mini
mental status assessment, asking questions regarding current date and time, ability to recall a
random name and address and the ability to count backwards from 20 and name the months
in reverse. Both the HVLT-R and OMC provide raw numerical scores, while the Mini-Cog
provides a dichotomous pass/fail score.
After this baseline testing was performed, women were instructed to start trospium chloride
extended release. Date and time of initiation was recorded. Subjects completed a medication
diary, recording the date and time of each pill taken on a grid chart for the entire study
period. Cognitive function was then reassessed using the Mini-Cog, HVLT-R and OMC at
Day 1, Week 1, Week 4 and Week 12 of medication usage. These time periods were
determined based on the pharmacokinetics of trospium chloride extended release. We also
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assessed pelvic floor function, specifically focusing on OAB symptoms. Pelvic floor and
bladder function were measured via three validated condition-specific quality of life
questionnaires: the Pelvic Floor Distress Inventory – Short Form 20 (PFDI-20)[23], the
Pelvic Floor Impact Questionnaire – Short Form 7 (PFIQ-7)[23] and the Pelvic Organ
Prolapse/Urinary Incontinence Sexual Function Questionnaire – Short Form 12
(PISQ-12)[24]. Both the PFDI-20 and PFIQ-7 contain urinary subscales: the UDI-6 and
UIQ-7, respectively. Urge urinary incontinence was defined as a positive response to
question 3 on the PFDI-20 indicating urine leakage with urge. The severity of OAB
symptoms were defined as a positive response to questions 1 and/or 3 on the PFDI-20
indicating severity of urgency (with or without leakage) and frequency.
Our primary outcome was a change in cognitive function, as determined by HVLT-R, at
four weeks after starting the anticholinergic medication. Secondary outcomes included the
severity of OAB symptoms in this clinic population, the time of onset of any change in
cognitive function, the time of onset of OAB symptom improvement and medication
compliance. Inclusion criteria consisted of English-literate women age 55 or older opting for
medical management of OAB. Exclusion criteria were the presence of pre-existing
comorbidities such as dementia, depression, and any other psychiatric diagnoses that may
affect cognitive function as determined by patient history and medical records; current use
of other anticholinergic medications or other agents known to affect cognitive function; and
medical conditions known to be adversely affected by anticholinergic therapy, such as
narrow-angle glaucoma, severe urinary retention and obstructive bowel disease.
Furthermore, women who met criteria for dementia on the baseline Mini-Cog were excluded
from the study. Prior or current use of an anticholinergic other than trospium chloride for the
treatment of OAB was not a reason for exclusion. Any women currently using a different
anticholinergic but electing to enroll in the study underwent a two-week washout period
prior to medication start.
Data were analyzed using SPSS 16.0 (Chicago, IL). Analysis was undertaken with
univariate analysis for descriptive variables and bivariate analysis using paired t test for
continuous variables, with a Bonferroni correction for multiple comparisons. The patient’s
baseline cognitive function served as the control for which variables at Day 1, Week 1,
Week 4 and Week 12 were each compared individually. This research was designed as a
pilot study to investigate the relationship between anticholinergic initiation and changes in
cognitive function as well as to answer questions regarding study design such as baseline
prevalence of OAB in our clinic population and the feasibility of assessing cognitive
function in this setting as part of the management of OAB. Therefore a control group was
not used. Rather, the subjects’ baseline scores served as the comparison for post-medication
cognitive performance using paired t-tests as described above. A convenience sample of 50
subjects was chosen. A p value <0.05 was considered significant.
RESULTS
During the study period 50 women were enrolled and 35 completed the primary assessment
at Week 4. Fifteen women dropped out prior to the primary assessment period, with the
main reason being discontinuation of the medication due to lack of efficacy. No subject
reported any subjective cognitive effects during the study period. Average age at enrollment
was 70.4 years and the majority of women were Caucasian (Table 1). More than three-
quarters of subjects had previously taken anticholinergic medication for the treatment of
OAB, with an average of 1.4 previous medications. Two-thirds of subjects reported severe
overactive bladder symptoms and almost three-quarters reported severe urge incontinence
based on validated questionnaire responses. At the time of enrollment, 13 of 35 women
(37.1%) were taking a different anticholinergic for the treatment of OAB and underwent a
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washout period. Baseline cognitive function was not impaired, as per protocol, based on an
intact Mini-Cog assessment, HVLT-R total score and OMC score. We then compared these
baseline cognitive function scores to post-treatment scores (Table 2). On Day 1 of
anticholinergic use, cognitive function showed a decline in the HVLT-R total score
(p=0.037) (Figure 1), the HVLT-R Delayed Recognition subscale (p=0.011) and the HVLT-
R Recognition Bias subscale (p=0.01). There were no changes seen in the other HVLT-R
subscales at that time. At Week 1 of anticholinergic use, there was a decline in the HVLT-R
Learning subscale (p=0.029) only. The other HVLT-R scores were unchanged from baseline
at Week 1, including those that had seen a decline on Day 1. At Week 4 of anticholinergic
use, the HVLT-R Total Recall subscale score was improved over baseline (p=0.02), with no
differences in the other HVLT-R scores. At Week 12, there were no statistical differences in
cognitive function compared to baseline HVLT-R scores. These analyses were based on
paired t-tests used to compare each follow-up point to its baseline score. When we instituted
a Bonferroni correction for multiple comparisons the changes in the HVLT-R subscales of
Delayed Recognition (p=0.011) and Recognition Bias (p=0.01) remained significant. The
OMC remained stable throughout the testing period, with no significant changes seen at any
time points. The Mini-Cog assessment showed a decline as early as Day 1, with a nadir at
Week 4 of 90.9%. It was noted to improve at Week 12 in the women who were still on the
anticholinergic medication. We also compared all cognitive outcomes between those women
who underwent a washout period at the time of enrollment due to current anticholinergic use
and those not currently taking an anticholinergic at the time of enrollment. There were no
differences in cognitive function outcomes at any time point between these two groups.
When assessing pelvic floor and bladder symptoms, we did not see a significant
improvement until Week 4, based on both PFDI-20 and PFIQ-7 total scores and UDI-6 and
UIQ-7 subscale scores. (Table 3) These changes remained significant after a Bonferroni
correction for multiple comparisons. Pelvic floor and bladder symptoms improved further at
Week 12 based on PFDI-20, PFIQ-7 and UDI-6 scores. There was no change in sexual
function based on PISQ-12 scores, but only 15 subjects were sexually active at the time of
enrollment, with no change in sexual status during the study period.
When assessing compliance, the overall medication discontinuation rate was 57.1% (20/35)
by 12 weeks, with an average time to discontinuation of 29.9 days as determined by
medication diary and interview. Leading reasons included lack of efficacy (28.6%), expense
of medication (8.6%), constipation (8.6%), dry mouth (2.9%), headache (2.9%), and nausea
(2.9%). No subjects cited cognitive dysfunction as a reason for discontinuation and no
subjects were withdrawn from the study for adverse events.
DISCUSSION
The mainstay of treatment for the highly prevalent condition OAB is anticholinergic
medication, a class of drugs known to interfere with cognitive function. OAB is more
prevalent in the elderly population - a group known to have increased cognitive dysfunction.
Therefore, it is essential to understand the effect of anticholinergics on cognitive function. In
our group of post-menopausal women, we found observed fluctuations in cognitive function
after beginning a new anticholinergic medication. While some cognitive changes were seen
as early as one day after medication start, other changes did not appear until one week of
medication use. By four weeks of medication use, cognitive function returned to baseline
and did not fluctuate after that time, up to 12 weeks after medication initiation. No subjects
reported any subjective changes in cognitive function.
Anticholinergic drug exposure in the elderly has been shown to have variable effects. Han et
al. demonstrated that anticholinergic exposure with multiple medications has a cumulative
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effect on cognitive function.[25] This cumulative effect was confirmed in a recent
longitudinal study of over 13,000 elderly adults.[26] Ancelin et al. found that elderly adults
taking various anticholinergics had multiple areas of cognitive dysfunction: reaction time,
attention, memory, recall, visuospatial construction, and language tasks.[27] In contrast, a
randomized trial of healthy elderly volunteers showed no short-term differences in cognitive
function between OAB anticholinergics and placebo.[28] Staskin et al. found no difference in
cognitive testing between trospium chloride and placebo, and no measurable trospium
chloride in the CNS.[29] Because cognitive function is not routinely evaluated by
practitioners treating OAB, the true rate of cognitive impairment associated with
anticholinergic use is unknown.[4]
Evaluation of baseline urinary symptoms in our clinic population demonstrated that most
women are severely affected by OAB and have tried at least one prior anticholinergic
medication prior to seeking care with a specialist. This may be helpful in understanding
baseline disease severity in women seeking specialty care for management of OAB. We also
found that there was a delay between the onset of changes in cognitive function and OAB
symptom improvement after medication start. While cognitive changes occurred early, OAB
symptoms were not found to improve until 4 weeks after starting anticholinergic medication.
Therefore, it is important to realize that side effects, specifically in cognitive function, may
be occurring prior to symptom improvement, and normalization of cognitive function may
be found at time of peak effects of anticholinergic medications. In regards to compliance, we
found that the discontinuation rate for this anticholinergic medication was high, with over
half of women stopping the medication by the end of the study period. Average time to
discontinuation was 4 weeks, which was the same time when we first observed an
improvement in OAB symptoms. Among those who continued therapy to 12 weeks, we
observed further improvement of symptoms. Clinicians may consider advising their patients
to try medication for at least 4 weeks, as symptom improvement may not take place until
that time. We also described leading reasons for medication discontinuation, which may
provide further help in counseling patients as to medication expectations.
We were interested to see an improvement in the HVLT-R total score at Week 4 and the
Mini-Cog at Week 12. Our repeated testing likely led to these improved cognitive scores due
to a learning effect, which has been reported previously.[14] While the HVLT-R offers a
different set of 12 words with each administration, the OMC and Mini-Cog have repetitive
elements. Frequent administration of all three tests may have been an intervention in itself,
by providing memory exercises for the subjects. In designing an expanded version of this
study we plan to have less frequent cognitive testing and the use of a placebo group to avoid
this learning effect.
We chose trospium chloride extended release as our anticholinergic medication for this
study for a number of reasons. We chose a single agent for all subjects in order to avoid the
effect of variation in drug absorption, action and efficacy. Due to its molecular properties,
this drug has a relatively low capacity to penetrate the blood-brain barrier (BBB) and exert
cognitive effects. A drug’s ability to cross the BBB is based on not only its size but also its
polarity and lipophilic properties.[17] Trospium chloride, as a quarternary amine, is large,
highly polar, and hydrophilic and thus is relatively impermeable to the BBB. Furthermore,
trospium chloride is a known P-glycoprotein ligand and is actively removed from the central
nervous system via efflux.[30] There are abundant data demonstrating cognitive effects of
non-selective anticholinergics that do cross the BBB.[9,17,31] However, there is less direct
evidence of whether trospium chloride exerts these effects due to its unique properties.
trospium chloride does have some drawbacks as well: 1) it has reduced oral bioavailability,
thus requiring that it be taken with a full glass of water one hour before meals, 2) it requires
a dose reduction for subjects with decreased renal function and 3) it may compete with other
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drugs that are excreted in the kidneys, including digoxin and metformin, although studies
have not shown this effect.[11,32] At the time of study recruitment trospium chloride was a
relatively new medication, and it was more likely that our study population was naïve to it.
The principal limitation of this study is the lack of a control group, which may lead to
misclassification bias. This project was designed as a pilot study to gather information on
the effect of a unique anticholinergic on cognitive function in postmenopausal women in our
clinic population, as well as the timing of onset of these changes in relation to improvement
in OAB symptoms and the baseline severity of OAB. A clinically meaningful change in
HVLT-R total score has been reported to be 6 points.[29] Our findings approached this cut-
off, with a mean and standard deviation decline of 4.2 ± 12.2 points at Day 1. Because we
used a convenience sample of subjects, we did not aim to have an adequate sample size to
meet power in the current study, which would have required significantly more subjects.
Based on our data, we can now design an adequately powered placebo-controlled study to
further address the effect of anticholinergics on cognitive function in this population. There
is also potential for selection bias due to the use of subjects that were naïve to
anticholinergics and those who had previously tried these medications. However, no subjects
had previously taken trospium chloride and we found no difference in outcomes between
these two groups. Another limitation is the accuracy of the chosen cognitive function tests to
discriminate small but potentially meaningful changes in cognitive function. We used
validated tools in our study but this remains a potential confounding variable. A final
limitation is the fact that we did not assess pelvic floor and bladder symptoms between
Weeks 1 and 4, so we cannot say exactly when the time to improvement in symptoms
occurred. However, this was not the main aim of the study.
The major strength of this study is the prospective design, with baseline cognitive function
obtained for comparison to post-treatment time-points. Anyone displaying baseline
cognitive dysfunction was excluded from the study. We used a single anticholinergic
medication for all subjects in order to avoid any variation in pharmacokinetics, efficacy or
side effects that could be due to multiple medications. In addition, all subjects were either
naïve to anticholinergic or had undergone a washout period prior to obtaining baseline
cognitive testing. All medications were reviewed prior to enrollment to confirm this. When
we compared the naïve group to the washout group, we found no differences in any of the
cognitive or pelvic floor outcomes. Finally, the interdisciplinary collaboration involved in
this study allowed us to look at multiple facets of medication effects, including the
pharmacokinetics of the drug (timing of effects seen), and the interplay between onset of
cognitive changes and the improvement in OAB symptoms.
CONCLUSION
OAB is a wide-spread condition with far-reaching consequences. As our population ages
and the prevalence of OAB increases, anticholinergic medication will remain a mainstay in
the management of this disease. Understanding the side effects of the anticholinergic
medications that we prescribe is critical. The data obtained from this study will facilitate the
design of a large-scale longitudinal clinical trial, which will expand on our understanding of
the current topic. As providers, we must continue to provide treatment options for OAB that
are both effective and safe.
Acknowledgments
This project was supported by the IBM Fund Award (Junior Faculty Development Grant, University of North
Carolina). The content is solely the responsibility of the authors and does not necessarily represent the official
views of the grant sponsors.
Geller et al. Page 7














1. Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, et al. Prevalence and
burden of overactive bladder in the United States. World J Urol. 2003; 20(6):327–336. [PubMed:
12811491]
2. Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, et al. An International
Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the
terminology for female pelvic floor dysfunction. Int Urogynecol J. 2010; 21(1):5–26. Epub
2009/11/26. [PubMed: 19937315]
3. Scheife R, Takeda M. Central nervous system safety of anticholinergic drugs for the treatment of
overactive bladder in the elderly. Clin Ther. 2005; 27(2):144–153. Epub 2005/04/07. [PubMed:
15811477]
4. Liberman JN, Hunt TL, Stewart WF, Wein A, Zhou Z, Herzog AR, et al. Health-related quality of
life among adults with symptoms of overactive bladder: results from a U.S. community-based
survey. Urology. 2001; 57(6):1044–1050. Epub 2001/05/30. [PubMed: 11377301]
5. Sexton CC, Coyne KS, Thompson C, Bavendam T, Chen CI, Markland A. Prevalence and effect on
health-related quality of life of overactive bladder in older americans: results from the epidemiology
of lower urinary tract symptoms study. J Am Geriatr Soc. 2011; 59(8):1465–1470. Epub
2011/07/02. [PubMed: 21718275]
6. Hu TW, Wagner TH. Health-related consequences of overactive bladder: an economic perspective.
BJU Int. 2005; 96(Suppl 1):43–45. [PubMed: 16086679]
7. Hu TW, Wagner TH, Bentkover JD, Leblanc K, Zhou SZ, Hunt T. Costs of urinary incontinence
and overactive bladder in the United States: a comparative study. Urology. 2004; 63(3):461–465.
[PubMed: 15028438]
8. Sexton CC, Coyne KS, Vats V, Kopp ZS, Irwin DE, Wagner TH. Impact of overactive bladder on
work productivity in the United States: results from EpiLUTS. Am J Manag Care. 2009; 15(4
Suppl):S98–S107. Epub 2009/04/16. [PubMed: 19355804]
9. Kay GG, Abou-Donia MB, Messer WS Jr, Murphy DG, Tsao JW, Ouslander JG. Antimuscarinic
drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am
Geriatr Soc. 2005; 53(12):2195–2201. Epub 2006/01/10. [PubMed: 16398909]
10. Abrams P, Andersson KE, Buccafusco JJ, Chapple C, de Groat WC, Fryer AD, et al. Muscarinic
receptors: their distribution and function in body systems, and the implications for treating
overactive bladder. Br J Pharmacol. 2006; 148(5):565–578. [PubMed: 16751797]
11. Staskin DR, Harnett MD. Effect of trospium chloride on somnolence and sleepiness in patients
with overactive bladder. Curr Urol Rep. 2004; 5(6):423–426. [PubMed: 15541209]
12. Kaufer DI. Cholinesterase-inhibitor therapy for dementia: novel clinical substrates and
mechanisms for treatment response. CNS Spectr. 2002; 7(10):742–750. Epub 2004/03/23.
[PubMed: 15034499]
13. Callegari E, Malhotra B, Bungay PJ, Webster R, Fenner KS, Kempshall S, et al. A comprehensive
non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment
of overactive bladder. Br J Clin Pharmacol. 2011; 72(2):235–246. Epub 2011/03/12. [PubMed:
21392072]
14. Lackner TE, Wyman JF, McCarthy TC, Monigold M, Davey C. Randomized, placebo-controlled
trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in
cognitively impaired nursing home residents with urge urinary incontinence. J Am Geriatr Soc.
2008; 56(5):862–870. [PubMed: 18410326]
15. Pakulski C, Drobnik L, Millo B. Age and sex as factors modifying the function of the blood-
cerebrospinal fluid barrier. Med Sci Monit. 2000; 6(2):314–318. Epub 2001/02/24. [PubMed:
11208329]
16. Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug metabolism reviews. 2009;
41(2):67–76. Epub 2009/06/12. [PubMed: 19514965]
17. Pak RW, Petrou SP, Staskin DR. trospium chloride: a quaternary amine with unique
pharmacologic properties. Current urology reports. 2003; 4(6):436–440. Epub 2003/11/19.
[PubMed: 14622495]
Geller et al. Page 8













18. Biastre K, Burnakis T. trospium chloride treatment of overactive bladder. Ann Pharmacother.
2009; 43(2):283–295. [PubMed: 19193592]
19. STROBE statement--checklist of items that should be included in reports of observational studies
(STROBE initiative). Int J Public Health. 2008; 53(1):3–4. Epub 2008/06/05. [PubMed:
18522360]
20. Brandt J. The Hopkins Verbal Learning Test: development of a new memory test with six
equivalent forms. Clin Neuropsychol. 1991; 5:125–142.
21. Borson S, Scanlan JM, Chen P, Ganguli M. The Mini-Cog as a screen for dementia: validation in a
population-based sample. J Am Geriatr Soc. 2003; 51(10):1451–1454. Epub 2003/09/27.
[PubMed: 14511167]
22. Katzman R, Brown T, Fuld P, Peck A, Schechter R, Schimmel H. Validation of a short
Orientation-Memory-Concentration Test of cognitive impairment. Am J Psychiatry. 1983;
140:734–739. [PubMed: 6846631]
23. Barber MD, Walters MD, Bump RC. Short forms of two condition-specific quality-of-life
questionnaires for women with pelvic floor disorders (PFDI-20 and PFIQ-7). Am J Obstet
Gynecol. 2005; 193(1):103–113. Epub 2005/07/16. [PubMed: 16021067]
24. Rogers RG, Coates KW, Kammerer-Doak D, Khalsa S, Qualls C. A short form of the Pelvic Organ
Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12). Int Urogynecol J Pelvic Floor
Dysfunct. 2003; 14(3):164–168. discussion 8. Epub 2003/09/05. [PubMed: 12955337]
25. Han L, Agostini JV, Allore HG. Cumulative anticholinergic exposure is associated with poor
memory and executive function in older men. Journal of the American Geriatrics Society. 2008;
56(12):2203–2210. [PubMed: 19093918]
26. Fox C, Richardson K, Maidment ID, Savva GM, Matthews FE, Smithard D, et al. Anticholinergic
medication use and cognitive impairment in the older population: the medical research council
cognitive function and ageing study. J Am Geriatr Soc. 2011; 59(8):1477–1483. Epub 2011/06/29.
[PubMed: 21707557]
27. Ancelin ML, Artero S, Portet F, Dupuy AM, Touchon J, Ritchie K. Non-degenerative mild
cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study.
BMJ. 2006; 332(7539):455–459. Epub 2006/02/03. [PubMed: 16452102]
28. Lipton RB, Kolodner K, Wesnes K. Assessment of cognitive function of the elderly population:
effects of darifenacin. J Urol. 2005; 173(2):493–498. [PubMed: 15643227]
29. Staskin D, Kay G, Tannenbaum C, Goldman HB, Bhashi K, Ling J, et al. trospium chloride has no
effect on memory testing and is assay undetectable in the central nervous system of older patients
with overactive bladder. Int J Clin Pract. 2010; 64(9):1294–1300. Epub 2010/06/22. [PubMed:
20561092]
30. Ieiri I, Takane H, Otsubo K. The MDR1 (ABCB1) gene polymorphism and its clinical
implications. Clin Pharmacokinet. 2004; 43(9):553–576. Epub 2004/06/26. [PubMed: 15217301]
31. Van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein A. Tolterodine once-daily: superior
efficacy and tolerability in the treatment of the overactive bladder. Urology. 2001; 57(3):414–421.
Epub 2001/03/15. [PubMed: 11248608]
32. FDA. Sanctura XR ® (trospium chloride) Extended Release - full prescribing information. 2011.
http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022103s004lbl.pdf, editor.
Geller et al. Page 9














Changes in HVLT-R Total Score, plotted points are mean values
* p<.005
HVLT-R = Hopkins Verbal Learning Test - Revised
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    White 33 (94.3)
    Black 2 (5.7)





    Mild 11 (31.4)
    Severe 23 (65.7)
Baseline Urge Leakage
    None 3 (8.6)
    Mild 7 (20.0)
    Severe 25 (71.4)
Baseline HVLT-Rb Total Score 60.3±6.0
Baseline OMCc Score 25.1±3.1
Baseline Mini-Cog Pass Rate 35 (100)
Data presented as mean ± SD or n (%).
a.
OAB = overactive bladder
b.
HVLT-R = Hopkins Verbal Learning Test – Revised; maximum possible score is 76.
c.
OMC = Orientation, Concentration and Memory test; maximum possible score is 28.
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